EBITDA Margin % is calculated as EBITDA divided by its Revenue. Virax Biolabs Group's EBITDA for the
six
months ended in Sep. 2025 was $-2.37 Mil. Virax Biolabs Group's Revenue for the
six
months ended in Sep. 2025 was $0.00 Mil. Therefore, Virax Biolabs Group's EBITDA margin for the quarter that ended in Sep. 2025 was -118,450.00%.
Virax Biolabs Group (NAS:VRAX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Virax Biolabs Group EBITDA Margin % Related Terms
Virax Biolabs Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRAX vs BBLG, PKTX, OGEN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Virax Biolabs Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a EBITDA Margin % of -118,450.00% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Virax Biolabs Group and its competitors. According to the industry distribution chart, Virax Biolabs Group ranks #922 out of 936 companies in the Biotechnology industry, placing it in the top 98.5%.
Is Virax Biolabs Group's EBITDA Margin % too high?
Virax Biolabs Group's current EBITDA Margin % is -118,450.00%. Based on the distribution chart, Virax Biolabs Group ranks #922 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's EBITDA Margin % compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #922 out of 936 companies for EBITDA Margin %. This places Virax Biolabs Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current EBITDA Margin % is -118,450.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current EBITDA Margin % is -118,450.00%. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current EBITDA Margin % is -118,450.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15.
GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.
Key valuation signals for VRAX:
EBITDA Margin %: -118,450.00%
GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score
Get the complete analysis for VRAX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
